Neurogene

NEUROGENE INC

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

xr:d:DAFlBgQqXKI:2,j:3472667867116897537,t:23060606

News

Intraday Update

Markets

Movers

Trading Ideas

ARWR

EMBC

EXAS

HSAI

NGNE

POET

RKLB

SGMO

SMRT

SMTC

SRPT

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

oil-prices-5079975

Equities

Eurozone

Commodities

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

CMAX

HCWB

IONQ

TWST

Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November

Nvidia Corporation (NVDA)

Pre-Market Outlook

AMAT

AMGN

CMPO

LAZR

LUNR

NVDA

OMER

PRQR

RZLV

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Neurogene Inc

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

Neurogene to Participate in Upcoming Conferences

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Abeona Therapeutics

Anika Therapeutics

Annexon

Cidara Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Foghorn Therapeutics

Gossamer Bio

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Inhibrx Biosciences

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

ITeos Therapeutics

Monopar Therapeutics

Ocugen

Prime Medicine

AVITA Medical

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

Y-mAbs Therapeutics

HC Wainwright & Co.

BMO Capital

Stifel

Leerink Partners

Baird

Comments

Neurogene

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga